FGEN - FibroGen Inc Qarzning balans kapitallashuviga nisbati

FibroGen Inc (FGEN) grafik logotipi

FibroGen, Inc. (FGEN) uchun istiqbollar yangi dori vositalarining tasdiqlanishi va onkologik test natijalari bilan belgilanadi. Qarzning kitob qiymatiga nisbati tendentsiyasi bozor reaksiyasini aks ettiradi, bunda 0.00 qiymati metrika darajasini ifodalaydi. FibroGen, Inc. (FGEN) noyob Roxadustat preparati bilan buyrak anemiyasi terapiyasi sohasida yetakchilik qilmoqda, shu bilan birga, o'z biotexnologiya dasturlarini rivojlantirish uchun hozirda agressiv aktivlarni qayta tuzish va xarajatlarni kamaytirish choralarini amalga oshirmoqda.

FGEN (FibroGen Corporation) Qarzning balans qiymatiga nisbati tarixi 04.07.2022dan 08.01.2026gacha

FibroGen Inc (FGEN) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi FibroGen, Inc.|FGEN - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor qiymati FibroGen Corporation|FGEN - Qarz va naqd pullar hisobga olingan qiymat
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya uchun sof aktivlar FibroGen|FGEN - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga nisbati fibrogen.com|FGEN - Kompaniyaning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati FibroGen, Inc.|FGEN - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Qisqa muddatli qarzning o'z kapitaliga nisbati FibroGen Corp|FGEN - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans qiymatiga nisbati FibroGen Corporation
Kompaniyaning barcha koʻrsatkichlari tahlili:FGEN FibroGen, Inc.
FibroGen Corp asosiy tovari

Ushbu ko'rsatkich umumiy qarzdorlikning kapitalning balans qiymatiga nisbati sifatida hisoblanadi. Mazkur metrika moliyaviy leveraj darajasini va kreditorlarga bog'liqlik bilan bog'liq xatarlarni aniqlaydi. Biotechnologiyalari makroiqtisodiy tendentsiyalardan mustaqil bo'lgan FibroGen, Inc. (FGEN) uchun past leveraj uning defensiv aktiv sifatidagi maqomini tasdiqlaydi. Kompaniyaning umumiy qarzdorligining balans kapitaliga nisbatini tahlil qilish agressiv o'sish va barqarorlik o'rtasidagi muvozanatni ochib beradi. Ushbu nisbatning kamayishi likvidlik shoklari ehtimolini minimallashtiradi.

FibroGen, Inc. raqobatchilari

Balans kapitallashuviga qarzlar HLN (Haleon plc)|kenvue.com - Balans kapitallashuviga qarzlar|Qarzning balans kapitallashuviga nisbati Verona Pharma (VRNA)|MENS: Qarzning sof aktivlarga nisbati|LGND (Ligand Pharma) - Qarzning balans kapitallashuviga nisbati|Amneal Corp (AMRX) - Qarzning balans qiymatiga nisbati|PRGO (Perrigo Company plc) - Balans kapitallashuviga qarzlar|Balans kapitallashuviga qarzlar alvotech.com (ALVO)|Liquidia (LQDA) - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati GLPG (Galapagos N.V.)|ANIP: Qarzning balans kapitallashuviga nisbati|MNKD - Balans qiymatiga qarzlar|Qarzning balans qiymatiga nisbati Amphastar Pharmaceuticals AMPH|PCRX - Qarzning balans kapitaliga nisbati|Balans kapitallashuviga qarzlar ARS Pharmaceuticals, Inc. SPRY|Theravance Biopharma Inc (TBPH) - Qarzning sof aktivlarga nisbati|Balans kapitallashuviga qarzlar AQST (Aquestive Pharma)|Balans qiymatiga qarzlar SCPH|Tectonic Therapeutic, Inc. (TECX) - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati tonixpharma.com (TNXP)|China SXT Pharmaceuticals, Inc. (SXTC) - Balans kapitallashuviga qarzlar|Qarzlarning balans kapitallashuviga nisbati Eupraxia Pharmaceuticals, Inc. EPRX|Balans kapitallashuviga qarzlar BHST (BioHarvest)|EXOZ - Sof aktivlarga qarzlar|oramed.com (ORMP) - Balans kapitallashuviga qarzlar|ENTX (Entera Bio) - Qarzning balans kapitallashuviga nisbati|HYFT - Qarzning balans kapitallashuviga nisbati|Qarzning sof aktivlarga nisbati ABVC|Cumberland Pharma - Qarzning balans kapitallashuviga nisbati|Balans qiymatiga qarzlar Quantum BioPharma Corp (QNTM)|TELO (Telomir Pharmaceuticals) - Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati Rani Therapeutics Holdings RANI|SNYR (Synergy CHC Corporation) - Balans kapitallashuviga qarzlar|RLYB: Balans qiymatiga qarzlar|Qarzning balans kapitallashuviga nisbati lexariabioscience.com|Qarzning balans qiymatiga nisbati Pulmatrix Corporation|PTHL - Qarzning balans qiymatiga nisbati|Qarzning sof aktivlarga nisbati Aptorum|LYRA (Lyra Therapeutics) - Balans kapitallashuviga qarzlar|Sof aktivlarga qarzlar IBO (Impact BioMedical, Inc.)|TNFA - Qarzning balans kapitallashuviga nisbati|Qarzning balans qiymatiga nisbati cbdMD Inc. YCBD|PRFX: Balans kapitallashuviga qarzlar|Altamira Therapeutics (CYTO) - Qarzning balans qiymatiga nisbati|Lipella Pharmaceuticals, Inc. - Qarzning balans qiymatiga nisbati|OptiNose Inc (OPTN) - Sof aktivlarga qarzlar|Balans kapitallashuviga qarzlar Pieris PIRS|Qarzlarning balans kapitallashuviga nisbati Procaps Group Corp|PTPI: Balans kapitallashuviga qarzlar|Qarzning sof aktivlarga nisbati qlsyy.net (QLI)|SLRN: Balans kapitallashuviga qarzlar|TFF Pharmaceuticals Inc. - Balans qiymatiga qarzlar